醒脑静注射液用于脑出血术后患者的疗效与安全性:Meta分析与系统评价
该系统评价纳入截至2024年1月31日八个数据库的随机对照试验,评估醒脑静注射液联合常规西药治疗脑出血术后患者的疗效与安全性。结果显示联合治疗可提高总有效率、降低15天内全因死亡率、减少血肿体积与血肿周围水肿、降低TNF-α水平、改善神经功能缺损、日常生活活动能力和意识水平,并发症更少且不良反应与对照组相当。但现有证据质量较弱且仅证明短期效果,需高质量RCT进一步验证。
要点
- 醒脑静联合常规西药可提高脑出血术后患者总有效率并降低15天内全因死亡率。
- 联合治疗可减少血肿体积和血肿周围水肿,降低TNF-α水平并改善神经功能与日常生活能力。
- 联合治疗并发症更少,不良反应与对照组相当,但证据质量较弱且仅限短期效果。
核心结论
- 醒脑静注射液联合常规西药可提高脑出血术后患者总有效率、降低15天内全因死亡率及并发症发生率,且耐受性良好。
- 现有研究证据等级较弱,仅能证明短期效果,仍需高质量随机对照试验进一步验证结论的准确性。
研究设计与样本
- 系统评价与Meta分析,检索八个代表性数据库自建库至2024年1月31日的随机对照试验,纳入脑出血术后接受醒脑静治疗的患者。
- 使用R4.2.2进行Meta分析,采用GRADE标准评价证据质量,并进行了试验序贯分析。
主要发现
- 联合治疗提高总有效率(RR=1.26;95%CI[1.21至1.32];p<0.0001)。
- 联合治疗降低15天内全因死亡率(RR=0.45;95%CI[0.30至0.67];p<0.0001)。
- 联合治疗减少血肿体积(MD=-4.72;95%CI[-7.43至-2.01];p=0.0006)和血肿周围水肿(MD=-4.11;95%CI[-8.11至-0.11];p=0.0441)。
- 联合治疗降低TNF-α水平(SMD=-1.61;95%CI[-2.23至-0.99];p<0.0001),改善神经功能缺损(SMD=-1.44;95%CI[-1.78至-1.11];p<0.0001)、日常生活活动能力(SMD=1.22;95%CI[0.78至1.66];p<0.0001)和意识水平(MD=2.08;95%CI[1.22至2.93];p<0.0001)。
- 联合治疗组并发症更低(RR=0.43;95%CI[0.35至0.54];p<0.0001),不良反应与对照组相当(RR=0.89;95%CI[0.55至1.45];p=0.6521)。
关键数值与推荐
- 总有效率RR=1.26(95%CI[1.21至1.32];p<0.0001)。
- 15天内全因死亡率RR=0.45(95%CI[0.30至0.67];p<0.0001)。
- 血肿体积MD=-4.72(95%CI[-7.43至-2.01];p=0.0006),血肿周围水肿MD=-4.11(95%CI[-8.11至-0.11];p=0.0441)。
- TNF-α水平SMD=-1.61(95%CI[-2.23至-0.99];p<0.0001),神经功能缺损SMD=-1.44(95%CI[-1.78至-1.11];p<0.0001)。
- 日常生活活动能力SMD=1.22(95%CI[0.78至1.66];p<0.0001),意识水平MD=2.08(95%CI[1.22至2.93];p<0.0001)。
临床怎么用
- 对于脑出血术后患者,可考虑在常规西药治疗基础上联合醒脑静注射液以短期改善总有效率、降低15天内死亡率和并发症。
- 联合用药时需关注不良反应,现有证据显示其与对照组相当,但仍应个体化评估并监测。
局限性
- 现有研究证据等级较弱,结论需谨慎解读。
- 仅能证明短期效果,缺乏长期疗效数据。
- 需高质量随机对照试验进一步验证结论的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracerebral haemorrhage (ICH) is the deadliest subtype of stroke. Surgery remains a vital measure for life-saving in emergency situations, however, the recovery of post-operative patients is not optimistic. This study aimed to evaluate the evidence of the efficacy and safety of Xingnaojing injection (XNJ) for post-operative patients of ICH. METHODS: From inception to 31 January 2024, we searched eight representative databases for randomized controlled trials on post-operative patients of ICH treated with XNJ. A meta-analysis was conducted using R4.2.2, and the quality of the evidence was evaluated by GRADE criteria. RESULTS: The results indicated that the combination of XNJ with conventional western medicine therapy improved the total efficiency rate (RR = 1.26; 95% CI [1.21 to 1.32]; p < 0.0001), reduced the all-cause mortality within 15 days (RR = 0.45; 95% CI [0.30 to 0.67]; p < 0.0001), decreased the volume of hematoma (MD = -4.72; 95% CI [-7.43 to -2.01]; p = 0.0006) and perihematomal edema (MD = -4.11; 95% CI [-8.11 to -0.11]; p = 0.0441), reduced the TNF-α levels (SMD = -1.61, 95% CI [-2.23 to -0.99], p < 0.0001), decreased neurological impairment (SMD = -1.44; 95% CI [-1.78 to -1.11]; p < 0.0001), improved the activities of daily living (SMD = 1.22; 95% CI [0.78 to 1.66]; p < 0.0001), and enhanced the consciousness level (MD = 2.08, 95% CI [1.22 to 2.93], p < 0.0001). In addition, the complications of the combination therapy group were lower (RR = 0.43; 95% CI [0.35 to 0.54]; p < 0.0001) and the adverse drug reactions were comparable to the control group (RR = 0.89; 95% CI [0.55 to 1.45]; p = 0.6521). The trial sequential analysis results showed that the sample size is sufficient. CONCLUSION: Current evidence indicates that XNJ can enhance the efficiency, reduce mortality, and lower the incidence of complications, while demonstrating good tolerability of post-operative patients of ICH. However, the level of evidence from existing studies is relatively weak, and only prove short-term effects, and high-quality RCTs are needed to further verify the accuracy of these conclusions. Systematic Review Registration: identifier (PROSPERO 2024 CRD42024503006). https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024503006, Identifier CRD42024503006.
引用
- Song Y, Xu F, Li S, et al. Efficacy and safety of Xingnaojing injection for post-operative patients of intracerebral haemorrhage: a meta-analysis and systematic review. Front Pharmacol. 2024. PMID: 38898923. doi:10.3389/fphar.2024.1411026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。